UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 000-55264 DYADIC® DYADIC INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 45-0486747 Sta ...

Dyadic International, Inc. (NASDAQ:DYAI) Q4 2021 Earnings Conference Call March 29, 2022 5:00 PM ET Company Participants Ping Rawson – Chief Financial Officer Mark Emalfarb – Chief Executive Officer Joe Hazelton – Chief Business Officer Conference Call Participants John Vandermosten – Zacks Paul Rosenbaum – SWR Corporation Robert Smith – The Center of Performance Investing Operator Good evening, and welcome to the Dyadic International’s 2021 Year-End Financial Results Conference Call. Currently all particip ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission file number: 000-55264 DYADIC INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 45-0486747 (State or other jurisdict ...

Dyadic International, Inc. (NASDAQ:DYAI) Q3 2021 Earnings Conference Call November 10, 2021 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President & Chief Executive Officer Conference Call Participants John Vandermosten - Zacks Robert Smith - Center for Performance Investing Operator Good evening, welcome to the Dyadic International's Third Quarter 2021 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management's pr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 000-55264 DYADIC® DYADIC INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 45-0486747 ...

Financial Data and Key Metrics Changes - As of June 30, 2021, the company's cash, cash equivalents, and investment-grade securities totaled $25.8 million, down from $27.4 million as of March 31, 2021 [30] - Research and development revenue for the quarter increased to approximately $937,000 compared to $524,000 for the same period a year ago [31] - Net loss for the quarter was approximately $3.8 million or $0.14 per share, compared to $2.7 million or $0.10 per share for the same period a year ago [34] Business Line Data and Key Metrics Changes - The number of ongoing research collaborations increased to 11 compared to 9 collaborations for the same period a year ago [31] - R&D expenses for the quarter increased to approximately $2.2 million, primarily due to Phase 1 clinical trial costs of DYAI-100, amounting to $1.5 million [32] - General and administrative expenses increased 18.5% to approximately $1.7 million compared to the same period a year ago [33] Market Data and Key Metrics Changes - The collaboration with Sorrento Therapeutics aims to develop a COVID-19 vaccine that can be rapidly manufactured and stored at room temperature or 2 to 8 degrees [11] - The Rubic Consortium collaboration intends to reduce Africa's dependence on foreign vaccine suppliers, targeting a population of 1.3 billion people [15] - The Syngene International collaboration aims to develop a COVID-19 vaccine candidate for the Indian subcontinent, which has an estimated population of 1.7 billion people [16] Company Strategy and Development Direction - The company is focused on leveraging its C1 protein production platform for biologic vaccine and drug production in the animal and human health markets [7] - The Sorrento license agreement is expected to validate the company's business model and provide significant upfront payments and milestone payments [20][14] - The company aims to disrupt the biomanufacturing of biologics and vaccines, with a focus on scalability and efficiency [19] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the progress made in advancing the DYAI-100 COVID-19 vaccine candidate towards a Phase 1 clinical trial [23] - The company anticipates that the Sorrento license agreement will significantly change its cash burn guidance for 2021 [35] - Management highlighted the potential for the C1 platform to support rapid development and manufacturing of future vaccines and drugs [22] Other Important Information - The company sold its equity interest in BDI Holdings and VLP Bio, realizing €1.3 million in cash and approximately a 30% return on investment [26] - The company is involved in several fully funded research projects exploring the expression of various proteins, including antibodies and bispecifics [28] Q&A Session Summary Question: Clarification on the Sorrento agreement and $4 million cited - Management clarified that the $4 million is for past and current expenditures related to the DYAI-100 vaccine candidate [37] Question: Long-term objectives with Rubic in South Africa - Management indicated that the collaboration addresses immediate needs and sets up infrastructure for future developments in various diseases [41] Question: Clarification on royalty terms and future products - Management confirmed that the current license agreement with Sorrento pertains solely to coronaviruses, with potential for renegotiation for future products [46]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 000-55264 DYADIC® DYADIC INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 45-0486747 Stat ...

Dyadic International, Inc. (NASDAQ:DYAI) Q1 2021 Earnings Conference Call May 13, 2021 5:00 PM ET Company Participants Ping Rawson – Chief Financial Officer Mark Emalfarb – President and Chief Executive Officer Conference Call Participants John Vandermosten – Zacks Investment Research David Snyder – Private Investor Lee Alper – Hammock Investors Dick Williams – Williams Resource Group Operator Good evening and thank you for holding. Welcome to Dyadic International’s First Quarter 2021 Financial Results Conf ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 000-55264 DYADIC® DYADIC INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 45-0486747 Sta ...

Dyadic International Inc (NASDAQ:DYAI) Q4 2020 Earnings Conference Call March 30, 2021 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Ronen Tchelet - Vice President of Research and Business Development Conference Call Participants Jason Kolbert - Dawson James John Vandermosten - Zacks Investment Research Operator Good evening. Thank you for holding. Welcome to Dyadic International's Fourth Quarter and Full Year 2020 Financial Resul ...